Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue: +27.0%
EPS: −40.3%
Free cash flow: −140.2%
Total debt: +4.46%

Quarter to September 2026, against a year earlier

Insider buying

25.11 0.92 −3.53%

Follow CAI

Alert me

Market cap: $7.4B
P/E: 77.7×
Fwd P/E: 254×
Dividend yield: —
F-score: n/a
Altman Z: 3.55
Beneish M: −2.71
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Caris Life Sciences,�Inc. 10-K filed Mar 3, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Mar 3, 2026 · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors: no comparison — no earlier filing on file